Ketamine Treatment Side Effects: When to See a Doctor

What Side Effects Does Ketamine Treatment Actually Cause?

Most ketamine side effects are dose-dependent, predictable, and limited to the infusion window or the two hours following a Spravato dose. The drug acts primarily as an NMDA-receptor antagonist, which explains both its rapid antidepressant effect and its dissociative properties. Knowing which effects are expected versus which are warning signs lets patients and caregivers respond appropriately rather than either dismissing something serious or panicking unnecessarily.

Dissociation and Perceptual Changes

Dissociation is the most commonly reported acute effect. Patients describe feeling detached from their body, seeing geometric patterns, or experiencing time distortion. A 2018 review published in CNS Drugs reported dissociation in 70 to 80% of patients receiving sub-anesthetic IV ketamine for depression [1]. These effects peak during the infusion and resolve within 30 to 60 minutes of completion for most patients.

Perceptual changes do not, by themselves, require emergency care. They do warrant a call to your provider if they persist beyond two hours after the infusion ends, recur spontaneously the following day, or are accompanied by paranoid ideation that does not settle.

Cardiovascular Effects

Ketamine stimulates the sympathetic nervous system, producing transient increases in heart rate and blood pressure. A 2021 analysis in Anesthesia and Analgesia documented a mean systolic blood pressure rise of approximately 20 to 30 mmHg during subanesthetic infusions [2]. For most patients with normal baseline cardiovascular function, this is clinically manageable and self-limiting.

Patients with uncontrolled hypertension, recent myocardial infarction, or known intracranial hypertension face meaningfully higher risk. The FDA label for Spravato lists cardiovascular disease as a condition requiring pre-treatment assessment [3].

Nausea and Vomiting

Nausea is the most common non-dissociative side effect. In a randomized controlled trial published in JAMA Psychiatry (N=71), nausea occurred in approximately 17% of participants receiving IV ketamine versus 5% in the placebo arm [4]. Most clinics pre-treat with ondansetron 4 mg IV or oral to reduce this risk.

Persistent vomiting lasting more than six hours after treatment, or vomiting combined with severe abdominal pain, warrants contact with your prescribing team that day.

Which Ketamine Side Effects Are Warning Signs?

A small subset of side effects signal something more serious. These require either a same-day call to your ketamine provider or an immediate visit to an emergency department. Identifying them early matters.

Chest Pain or Significant Palpitations

Chest pain during or after a ketamine infusion may reflect arrhythmia or hypertensive surge. Call 911 or go to the nearest ER if you develop chest pain that is pressure-like, radiates to your arm or jaw, or is accompanied by shortness of breath. Ketamine's sympathomimetic effect can, in rare cases, precipitate clinically significant tachyarrhythmia, particularly in patients with pre-existing structural heart disease [2].

Severe or Prolonged Psychosis

A single dissociative episode during treatment is expected. Psychotic symptoms that persist beyond four hours post-infusion, or that recur on subsequent days without re-dosing, may indicate that ketamine has triggered or unmasked an underlying psychotic disorder. The American Psychiatric Association's 2017 Consensus Statement on the use of ketamine in mood disorders explicitly lists "active or history of psychotic disorders" as a contraindication [5].

If a patient or family member notices frank hallucinations, paranoid delusions, or disorganized speech the following morning, that is a same-day call to the prescribing psychiatrist, not a "wait and see" situation.

Urinary Symptoms

Ketamine-associated uropathy is the most underappreciated serious adverse effect in therapeutic settings. Originally described in high-dose recreational users, it has since been documented in patients receiving repeated therapeutic courses. A 2018 case series in BJU International described bladder inflammation, ureteral stricture, and upper-tract damage in patients who received ketamine at therapeutic doses over periods of six months or longer [6].

Symptoms to report immediately include:

• Blood in the urine (hematuria)
• Urinary frequency more than once per hour
• Severe pelvic or flank pain
• Inability to fully empty the bladder

These symptoms should prompt same-day urology referral, not expectant management. Cessation of ketamine is often required to halt progression.

Respiratory Depression

At subanesthetic doses used for depression (typically 0.5 mg/kg IV over 40 minutes), ketamine largely preserves respiratory drive. This is one property that distinguishes it from opioids. At higher doses, or when combined with benzodiazepines, alcohol, or opioids, respiratory depression can occur [7]. Any episode of slow or stopped breathing requires 911 activation immediately.

How Are Ketamine Side Effects Diagnosed and Monitored?

Monitoring During the Infusion

All accredited ketamine infusion clinics should monitor blood pressure, heart rate, and oxygen saturation continuously throughout the infusion. The FDA's Spravato REMS (Risk Evaluation and Mitigation Strategy) program mandates that patients receiving esketamine be monitored in a certified healthcare setting for at least two hours after each dose [3]. This is not optional. Clinics that allow unsupervised administration or early discharge before two hours violate the REMS requirements.

Baseline Screening Before Starting Treatment

A complete pre-treatment evaluation should include:

• Cardiovascular history and resting blood pressure
• Urinary symptom questionnaire (e.g., AUASI for male patients, ICIQ for females)
• Psychiatric screening to exclude active psychosis or personal or family history of schizophrenia
• Substance use history, including prior ketamine misuse
• Medication reconciliation to flag CNS depressant combinations

The American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) published practice guidelines recommending this baseline evaluation for all patients entering a ketamine treatment course [8].

Ongoing Monitoring Between Sessions

Patients on extended treatment courses (six or more infusions over weeks to months) may need periodic reassessment. Urinary symptom screening at least every three months is reasonable for patients continuing beyond an initial six-infusion series. Liver function tests may be warranted for patients on maintenance schedules, as hepatotoxicity has been reported with chronic high-frequency use in case reports published in Alimentary Pharmacology and Therapeutics [9].

The HealthRX clinical team uses the following decision framework for patients asking whether a symptom needs attention. During the infusion or within two hours: contact the administering clinic directly. Two to twenty-four hours post-infusion: use the Red/Yellow categories below. Beyond twenty-four hours: call your prescribing provider during business hours unless a Red symptom is present.

Red (call 911 or go to ER):

• Chest pain, pressure, or radiation to arm or jaw
• Breathing rate below 10 breaths per minute or loss of consciousness
• Seizure
• Frank hematuria (visibly bloody urine) with flank pain
• Inability to urinate with bladder pain

Yellow (call your ketamine provider same day):

• Dissociation or perceptual disturbance persisting beyond four hours
• Blood pressure reading above 180/110 mmHg at home
• Nausea and vomiting lasting more than six hours
• Urinary frequency greater than once per hour without infection
• New or worsening depressive symptoms within 24 hours of infusion (may indicate paradoxical response)
• Dysphoria, agitation, or mood instability persisting beyond the same evening

Green (monitor at home, mention at next appointment):

• Mild headache resolving within a few hours
• Fatigue or drowsiness the day of treatment
• Brief dizziness when standing after the infusion
• Vivid dreams the night of treatment

Causes of Ketamine Treatment Side Effects

Understanding the mechanism behind each side effect helps patients contextualize what they experience and communicate it clearly to their provider.

NMDA Receptor Antagonism

Ketamine blocks NMDA-type glutamate receptors throughout the brain. This action generates the dissociative and hallucinogenic effects and also drives the rapid antidepressant response via downstream AMPA receptor potentiation and BDNF release. A 2016 paper in Nature identified ketamine's active metabolite (2R,6R)-hydroxynorketamine as contributing to antidepressant effects without direct NMDA blockade [10], which has shaped next-generation drug development. The dissociation and perceptual effects are largely attributed to NMDA blockade in the thalamocortical circuits.

Sympathomimetic Mechanism

Ketamine inhibits catecholamine reuptake, producing a surge of norepinephrine and dopamine at sympathetic synapses. This is why blood pressure and heart rate rise during infusion. This same mechanism can cause anxiety or agitation in some patients in the immediate post-infusion period [2].

Urinary Tract Mechanism

Ketamine and its metabolites, particularly norketamine, are excreted via the renal system and appear to exert direct urothelial toxicity. Bladder biopsies from affected patients show denuded epithelium, subepithelial fibrosis, and inflammatory infiltrate. A 2013 study in European Urology (N=59 ketamine-associated cystitis patients) showed that 63% had upper urinary tract involvement at diagnosis [11]. Dose and duration of exposure are the primary modifiers of risk.

Treatment for Ketamine Treatment Side Effects

Managing Acute Dissociation

No pharmacologic reversal agent exists for ketamine dissociation the way naloxone reverses opioids. Management is supportive: a quiet, low-stimulus environment, verbal reassurance from clinic staff, and time. Benzodiazepines (e.g., midazolam 1 to 2 mg IV) are occasionally used in clinical settings for severe agitation during or after infusion, though their routine use is debated because they may blunt the antidepressant response [1].

Managing Blood Pressure Spikes

Clinics typically treat intraprocedural hypertension above 180/110 mmHg with IV labetalol or oral clonidine depending on protocol. Patients with known hypertension should have their antihypertensive regimen optimized before starting ketamine treatment [2].

Managing Nausea

Pre-treatment with ondansetron 4 mg IV is standard at most centers. For patients who still experience significant nausea, some clinics add dexamethasone 4 to 8 mg IV or switch to an oral aprepitant regimen before subsequent sessions. Fasting for at least two hours before infusion also reduces nausea risk [4].

Managing Ketamine Cystitis

The most effective treatment for ketamine-associated uropathy is stopping ketamine. A 2016 systematic review in BJU International found that urinary symptoms improved in the majority of patients who ceased ketamine within six months of symptom onset [12]. For patients with irreversible bladder damage, urological management may include intravesical hyaluronic acid, hydrodistension, or, in severe cases, cystectomy. This is why early reporting of urinary symptoms is so important.

When Dose or Delivery Route Adjustment Helps

Some side effects can be mitigated by switching between IV and intranasal delivery, adjusting the infusion rate, or reducing the dose. Slowing the infusion rate from 40 minutes to 60 minutes reduces peak plasma concentration and may lower the severity of dissociation and blood pressure elevation without significantly compromising antidepressant effect, based on pharmacokinetic modeling data [7]. Your prescribing physician can advise whether a dose adjustment is appropriate based on your symptom profile.

Special Populations and Elevated Risk

Patients With Psychiatric Comorbidities

Patients with bipolar disorder, borderline personality disorder, or a history of substance use disorder require closer monitoring during ketamine courses. Ketamine carries abuse potential. The DEA classifies it as Schedule III, and the FDA label for Spravato explicitly warns about the risk of dissociation and sedation that could impair driving and the potential for abuse and misuse [3]. Patients with active suicidal ideation, paradoxically, may experience transient worsening before improvement.

Older Adults

Blood pressure surges and fall risk from post-infusion dizziness are more consequential in adults over 65. A prospective study in The American Journal of Geriatric Psychiatry (N=33) found IV ketamine was tolerable in older adults with treatment-resistant depression but noted that cardiovascular monitoring required heightened vigilance [13]. Older patients should arrange supervised transportation and avoid stairs unassisted for several hours post-infusion.

Patients on Other CNS Medications

Combining ketamine with lithium is practiced in some treatment-resistant depression protocols but requires monitoring, as animal data raised early seizure concerns that have not translated consistently to humans. Combining ketamine with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of serotonin syndrome and hypertensive crisis. Concurrent opioid or benzodiazepine use raises respiratory depression risk and should be disclosed to the infusion team before every session [7].

How to Talk to Your Doctor About Ketamine Side Effects

Specific, time-stamped symptom reporting helps your provider make better decisions than vague descriptions do. Before your appointment, note:

1. The exact symptom and when it started relative to the infusion
2. Duration and whether it resolved fully
3. Any new medications, supplements, or substances taken in the 48 hours before the infusion
4. A numeric rating of severity on a 1 to 10 scale

The American Psychiatric Association's 2017 Consensus Statement recommends that all patients receiving ketamine for mood disorders have a named clinical contact for adverse event reporting between sessions [5]. If your clinic has not provided you with an after-hours contact number, request one before your next infusion.

Patients receiving Spravato through a certified outpatient program can report adverse events directly to the FDA via MedWatch at fda.gov/safety/medwatch. Filing a MedWatch report does not replace contacting your prescribing provider but does contribute to post-market safety surveillance.